YONGAN PHARMACEUTICAL(SZ:002365)2022-12-07 09:42Group 1: Company Production and Operations - The company currently has a production capacity of 34,000 tons for taurine, with an annual output of 24,000 tons [2] - The production capacity for ethylene oxide is 40,000 tons, but the output was low last year due to the project being in trial operation [2] - Approximately two-thirds of the ethylene oxide produced is sold overseas [3] Group 2: Cost Advantages and Market Position - The cost advantages of taurine production are primarily due to technological, scale, and raw material procurement advantages [3] - The company is actively increasing research and development efforts for taurine downstream products to meet diverse consumer needs [3] Group 3: Subsidiary Operations and Product Sales - The subsidiary, Kangjian Pharmaceutical, is currently operating normally with steady growth in online sales and improving offline channels [4] - The company is selling foreign health products such as natto kinase capsules and deep-sea fish oil soft capsules, and is working to introduce more foreign products [4] Group 4: Future Development Plans - The global demand for taurine is continuously growing, with significant development potential in the domestic market [4] - The company plans to enhance its marketing team and brand promotion efforts in 2015 to increase market share [4] - There are no known plans for major shareholders to reduce their holdings, as such decisions are personal and will be disclosed if the company is informed [5]